血清谷胱甘肽过氧化物酶 3 水平对肺癌患者的诊断价值。
Diagnostic value of serum glutathione peroxidase 3 levels in patients with lung cancer.
机构信息
Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital Jeonnam, Korea; Department of Internal Medicine, Chonnam National University Medical School Gwangju, Korea.
Department of Anatomy, Chonnam National University Medical School Gwangju, Korea; Center for Creative Biomedical Scientists, Chonnam National University Gwangju, Korea.
出版信息
Thorac Cancer. 2014 Sep;5(5):425-30. doi: 10.1111/1759-7714.12113. Epub 2014 Aug 25.
BACKGROUND
We selected glutathione peroxidase 3 (GPx3) as a specific candidate that is down regulated in patients with lung cancer. In this study, we examined the diagnostic value of serum GPx3, which is an extracellular protein and readily detectable in blood.
METHODS
We collected serum samples from 342 patients with lung cancer and 126 controls (normal healthy people and patients with benign diseases or other malignancies). We measured serum GPx3 levels using the enzyme-linked immunosorbent assay.
RESULTS
Mean serum GPx3 levels were significantly lower in the patient group compared with the control group (10.1 ± 5.0 μg/mL vs. 13.0 ± 5.8 μg/mL, P < 0.001). In addition, mean serum GPx3 levels tended to be lower in the patients without metastasis compared with those with metastasis (9.6 ± 4.5 μg/mL vs. 10.7 ± 5.7 μg/mL, P = 0.051). Furthermore, mean serum GPx3 levels had a significant difference according to initial treatments (P < 0.001). In other words, mean serum GPx3 levels were significantly lower in the surgery group (8.2 ± 4.1 μg/mL) compared with the concurrent chemoradiotherapy (11.5 ± 4.6 μg/mL, P < 0.001), chemotherapy (10.7 ± 5.6 μg/mL, P < 0.001), and supportive care groups (10.9 ± 4.8 μg/mL, P = 0.002).
CONCLUSION
Our results showed that serum GPx3 levels were significantly lower in the patients who underwent surgery, which indicates that the serum may have diagnostic value in patients at an operable stage of lung cancer, rather than those at a locally advanced or metastatic stage.
背景
我们选择谷胱甘肽过氧化物酶 3（GPx3）作为一种特定的候选物，其在肺癌患者中下调。在这项研究中，我们检查了血清 GPx3 的诊断价值，GPx3 是一种细胞外蛋白，在血液中很容易检测到。
方法
我们收集了 342 名肺癌患者和 126 名对照者（正常健康人和良性疾病或其他恶性肿瘤患者）的血清样本。我们使用酶联免疫吸附试验测量了血清 GPx3 水平。
结果
与对照组相比，患者组的平均血清 GPx3 水平显著降低（10.1 ± 5.0μg/mL 比 13.0 ± 5.8μg/mL，P < 0.001）。此外，无转移患者的平均血清 GPx3 水平较有转移患者低（9.6 ± 4.5μg/mL 比 10.7 ± 5.7μg/mL，P = 0.051）。此外，根据初始治疗，平均血清 GPx3 水平有显著差异（P < 0.001）。换句话说，与同期放化疗组（11.5 ± 4.6μg/mL，P < 0.001）、化疗组（10.7 ± 5.6μg/mL，P < 0.001）和支持治疗组（10.9 ± 4.8μg/mL，P = 0.002）相比，手术组的平均血清 GPx3 水平显著降低（8.2 ± 4.1μg/mL）。
结论
我们的结果表明，手术患者的血清 GPx3 水平显著降低，这表明血清在可手术肺癌患者中具有诊断价值，而不是在局部晚期或转移性肺癌患者中。
Zotero 插件